In the United States, breast cancer is one of the most common types of cancer among women, being the second cause of cancer‐related deaths. Despite early detection methods and available treatments, breast cancer incidence is increasing worldwide. Some malignant cells have the potential to migrate and invade, metastasizing to distant organs and tissues. Current treatments include surgery, chemotherapy, and radiotherapy. These treatments usually produce side effects that have a negative influence in the quality of life of the patients. Additional studies are necessary to identify candidate natural compounds targeting specific molecules and receptors expressed in breast cancer cells. For example, CXCR4 is a G protein‐coupled receptor known to be one of the major proteins involved in metastasis of breast cancer. It mediates migration towards tissues expressing its specific ligand CXCL12. Natural compounds such as resveratrol, a plant polyphenol commonly found in grapes, peanuts and berries, among other, has shown anti‐proliferative, anti‐estrogenic, and antioxidant properties. We aimed to study the effect of resveratrol on CXCR4‐mediated cell migration. We hypothesize resveratrol will inhibit the ligand‐receptor relation between CXCR4 and CXCL12 decreasing the migration. To accomplish this, we conducted a wound healing assays, in Hs578t breast carcinoma‐cell line and MCF 7 breast adenocarcinoma‐cell lines treated with 25, 50, 100, and 200 μM of resveratrol in the presence of 100 ng/mL of CXCL12. As an internal control we used AMD3100, an antagonist of CXCR4. The results on Hs578t carcinoma cells did not show significant differences in the migration compared to the controls. However, this preliminary data suggest that there is a decrease in migration in the cells treated with 25 and 100 μM of resveratrol, compared to the AMD3100. Regarding MCF‐7 adenocarcinoma cells, we did not observe significant differences in cell migration. Additional experimental replicates are necessary to validate these results. In addition, we are currently studying other malignant and non‐malignant cell lines, including: CCD‐1097 and CCD‐1074 to identify cell specific responses to resveratrol, mediated by the CXCR4‐CXCL12 signaling pathway.Support or Funding InformationNIH‐NIGMS #2R25GM096955This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.